Pharmaceuticals, Biotechnology and Life Sciences
ProKidney Corp., a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced the pricing of an…
Bristol Myers Squibb presented results from the Phase 3 CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo® (nivolumab) plus Yervoy® (ipilimumab)…
• Conference call and webcast to be held tomorrow, January 2, at 8:30am ET (5:30am PT) LA JOLLA, Calif.–(BUSINESS WIRE)–$LBPH…
Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right
AstraZeneca said Tuesday it has made agreements in the product liability litigations related to Nexium and Prilosec. The company said…
Moderna announced Wednesday positive results from a clinical trial of mRNA-1083, its combination mRNA combination flu/COVID vaccine.
AIDS Healthcare Foundation (AHF) acknowledged today pharmaceutical company Johnson & Johnson’s (J&J) announcement that it will not enforce its patent for the multi-drug resistant tuberculosis treatment SIRTURO (bedaquiline) for 134 low- and middle-income countries—a significant step in ending the global TB crisis for a preventable, treatable, and curable disease.
Regeneron Pharmaceuticals and Sanofi have received U.S. Food and Drug Administration (FDA) acceptance for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat children aged 1 to 11 years with eosinophilic esophagitis (EoE).
ABRYSVO recommended by CDC Advisory Committee for pregnant persons 32 through 36 weeks gestation to help protect infants from respiratory…
AiCuris Anti-infective Cures AG has received milestone payments in the amount of EUR €30 million from its licensing partner MSD (Merck) after the U.S. FDA’s approval for first-in-class antiviral agent PREVYMIS® in a new indication – the prophylaxis of CMV disease after kidney transplant in Donor CMV-seropositive/Recipient CMV-seronegative patients.